Benzinga
Benzinga
Benzinga
martes, septiembre 29

Celularity Inc

CELUNASDAQ
Trade with Public
Trade with Public
$1.40
0.021.45%
al cierre: Sep 25, 5:00 PM EST
$1.40
0.021.45%
Premercado: 4:42 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Celularity Financials

Celularity (CELU) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Stock Market: Will S&P 500 Open Up or Down Today?

Will S&P 500 open higher? Polymarket odds hit 65% as Wall Street digests Fed independence debates, crypto sanctions, and cooling oil prices.
Rishabh Mishra

Nasdaq Down 1%; Signet Jewelers Earnings Top Views

Avi Kapoor

PRO
Celularity Raises FY24 Expected Net Sales Guidance From $50M-$56M To $54M-$60M

Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to $8.9 Million Marks the
Benzinga Newsdesk

PRO
Celularity Provides Corporate Update; Says The Acquisition Of Rebound Adds To Our Portfolio Of Placental-Derived Advanced Biomaterial Products, Sales Of Which Through The First Half Of 2024 Were In Excess Of $24M; Guidance Of Expected Combined Net Sales Of Our Advanced Biomaterial Product And Biobanking Businesses To Be In The Range Of $50M-$56M

Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO.Dear
Benzinga Newsdesk

PRO
Celularity FY23 Revenue Of $22.8M; Sees Q1 Revenue $14.8M; Expected Combined Net Sales For The First Half 2024 Are $25.8M-$27.8M

For the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the $10.25 million to $11.5 million guidance range previously
Benzinga Newsdesk

PRO
Celularity Says That Its Expected Net Sales For Q1 2024 Are Trending Ahead Of The Expectations It Announced In February For Its Advanced Biomaterial Products And Biobanking Businesses; Implements Planned 2024 SG&A Reductions And Manufacturing Ramp For Advanced Biomaterial Products

Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expenses
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved